Janssen RA - Search Results

1

Bispecific monoclonal antibodies for intravenous treatment of carcinoma patients: immunobiologic aspects.

Kroesen BJ, Janssen RA, Buter J, Nieken J, Sleijfer DT, Mulder NH, De Leij L. Kroesen BJ, et al. Among authors: janssen ra. J Hematother. 1995 Oct;4(5):409-14. doi: 10.1089/scd.1.1995.4.409. J Hematother. 1995. PMID: 8581377 Clinical Trial.

2

Recovery from cytomegalovirus infection is associated with activation of peripheral blood lymphocytes.

van den Berg AP, van Son WJ, Janssen RA, Brons NH, Heyn AA, Scholten-Sampson A, Postma S, van der Giessen M, Tegzess AM, de Leij LH, et al. van den Berg AP, et al. Among authors: janssen ra. J Infect Dis. 1992 Dec;166(6):1228-35. doi: 10.1093/infdis/166.6.1228. J Infect Dis. 1992. PMID: 1385546

3

Recombinant interleukin 2 for metastatic renal cell carcinoma in haemodialysis patients.

Buter J, Janssen RA, Mulder NH, de Jong PE, de Leij L, Sleijfer DT. Buter J, et al. Among authors: janssen ra. Eur J Cancer. 1992;28A(10):1770-1. doi: 10.1016/0959-8049(92)90092-g. Eur J Cancer. 1992. PMID: 1389502 No abstract available.

4

Peripheral blood lymphocyte number and phenotype prior to therapy correlate with response in subcutaneously applied rIL-2 therapy of renal cell carcinoma.

Janssen RA, Sleijfer DT, Heijn AA, Mulder NH, The TH, de Leij L. Janssen RA, et al. Br J Cancer. 1992 Dec;66(6):1177-9. doi: 10.1038/bjc.1992.431. Br J Cancer. 1992. PMID: 1457361 Free PMC article.

5

Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis.

Sleijfer DT, Janssen RA, Buter J, de Vries EG, Willemse PH, Mulder NH. Sleijfer DT, et al. Among authors: janssen ra. J Clin Oncol. 1992 Jul;10(7):1119-23. doi: 10.1200/JCO.1992.10.7.1119. J Clin Oncol. 1992. PMID: 1607917 Clinical Trial.

6

Low-dose regimen of interleukin-2 for metastatic renal carcinoma.

Sleijfer DT, Janssen RA, Willemse PH, Martens A, de Leij L, de Vries EG, Mulder NH. Sleijfer DT, et al. Among authors: janssen ra. Lancet. 1990 Jun 23;335(8704):1522-3. doi: 10.1016/0140-6736(90)93057-v. Lancet. 1990. PMID: 1972445 No abstract available.

7

Immunomodulatory effects of intravenous BIS-1 F(ab')2 administration in renal cell cancer patients.

Janssen RA, Kroesen BJ, Buter J, Mesander G, Sleijfer DT, The TH, Mulder NH, de Leij L. Janssen RA, et al. Br J Cancer. 1995 Sep;72(3):795-9. doi: 10.1038/bjc.1995.414. Br J Cancer. 1995. PMID: 7669598 Free PMC article. Clinical Trial.

8

Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2.

Kroesen BJ, Buter J, Sleijfer DT, Janssen RA, van der Graaf WT, The TH, de Leij L, Mulder NH. Kroesen BJ, et al. Among authors: janssen ra. Br J Cancer. 1994 Oct;70(4):652-61. doi: 10.1038/bjc.1994.366. Br J Cancer. 1994. PMID: 7917912 Free PMC article. Clinical Trial.

9

The immunobiological effects of interleukin-2 in vivo.

Janssen RA, Mulder NH, The TH, de Leij L. Janssen RA, et al. Cancer Immunol Immunother. 1994 Oct;39(4):207-16. doi: 10.1007/BF01525983. Cancer Immunol Immunother. 1994. PMID: 7954522 Free PMC article. Review. No abstract available.

10

Prolonged continuous infusion of low-dose rIL-2.

Janssen RA, Buter J, The TH, Mulder NH, de Leij L. Janssen RA, et al. Br J Cancer. 1994 May;69(5):976-7. doi: 10.1038/bjc.1994.189. Br J Cancer. 1994. PMID: 8180034 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

262 results

Search Page

Filters